经营范围含第二类医疗器械销售【分支机构经营】；第二类医疗设备租赁【分支机构经营】；技术服 务、技术开发、技术咨询、技术交流、技术转让、技术推广；软件开发；医学研究和试验发展；专用设 备修理；租赁服务（不含许可类租赁服务）；第一类医疗设备租赁【分支机构经营】；第一类医疗器械 销售；第一类医疗器械生产【分支机构经营】；国内贸易代理；智能机器人的研发；人工智能行业应用 系统集成服务；基于云平台的业务外包服务；通用设备制造（不含特种设备制造）。（除依法须经批准 的项目外，凭营业执照依法自主开展经营活动）许可项目：第三类医疗器械经营【分支机构经营】；第 二类医疗器械生产【分支机构经营】；第三类医疗器械生产【分支机构经营】；第三类医疗设备租赁 【分支机构经营】；检验检测服务；医疗器械互联网信息服务【分支机构经营】。（依法须经批准的项 目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准） 企业名称上海电气集团医疗装备有限公司法定代表人彭勇注册资本30000万人民币国标行业科学研究和 技术服务业>专业技术服务业>工业与专业设计及其他专业技术服务地址上海市闵行区万源路2800号 （集中登记地）企 ...

圣湘生物公告称，2025年实现营收16.48亿元，同比增长13.04%；利润总额1.75亿元，归属于上市公司 股东的净利润1.98亿元，同比下降28.10%；扣非净利润1.65亿元，同比降18.64%。公司持续推进"诊疗 一体化"战略，研发投入约3.1亿元，占营收近20%，推出多款创新产品，新获近10项第三类医疗器械注 册证。此外，公司全资收购中山海济，控股红岸基元等，深化战略布局；多家参股、控股公司获评相关 称号，为发展注入新动能。 ...

Group 1 - The core focus of the regulatory efforts during the Spring Festival in Huangnan Prefecture is on food safety, drug safety, and market price supervision to ensure a stable market order and safe consumption environment [1][2] - In food safety regulation, over 160 food business units were inspected, including 12 large and medium-sized supermarkets, with 9 issues rectified on-site [1] - In drug safety regulation, there was a focus on high-risk drugs and medical devices, ensuring compliance in procurement, storage, and sales processes [1] Group 2 - Price supervision targeted essential goods such as grains, oils, and medicines, with increased efforts to combat price gouging and fraud [2] - Measurement and weighing instrument regulation was strengthened, particularly in markets and supermarkets, to protect consumer rights [2] - Fire safety inspections were conducted in crowded places, checking fire facilities and safety protocols, with 374 locations inspected and 21 hazards rectified [2]

天眼查显示，近日，海南凹凸医疗科技有限公司成立，法定代表人为毛卓森，注册资本200万人民币， 由河南易齿秀科技有限公司全资持股。 企业名称海南凹凸医疗科技有限公司法定代表人毛卓森注册资本200万人民币国标行业科学研究和技术 服务业>专业技术服务业>工业与专业设计及其他专业技术服务地址海南省海口市龙华区城西镇苍峰路4 号二楼企业类型有限责任公司（自然人投资或控股的法人独资）营业期限2026-2-11至无固定期限登记 机关海南省市场监督管理局 来源：市场资讯 经营范围含许可经营项目：第三类医疗器械生产；第三类医疗器械经营；第二类医疗器械生产（许可经 营项目凭许可证件经营）一般经营项目：第一类医疗器械销售；第一类医疗器械生产；第二类医疗器械 销售；网络技术服务；网络与信息安全软件开发；信息技术咨询服务；计算机系统服务；技术服务、技 术开发、技术咨询、技术交流、技术转让、技术推广；软件开发；会议及展览服务（出国办展须经相关 部门审批）；租赁服务（不含许可类租赁服务）；非居住房地产租赁（经营范围中的一般经营项目依法 自主开展经营活动，通过国家企业信用信息公示系统（海南）向社会公示） 序号股东名称持股比例1河南易齿秀科技 ...

Core Viewpoint - The article emphasizes the importance of facilitating the transformation of clinical innovations into medical products that benefit patients, highlighting Beijing's "Spring Rain Action" as a key initiative to enhance innovation in the medical and health industry [1] Group 1: Policy and Support Mechanisms - Beijing has established a "policy coordination + full-chain service" support system to optimize the innovation environment, combining top-level design with systematic policy support [2] - Since 2018, Beijing has implemented three rounds of collaborative innovation action plans in the medical and health sector, introducing measures to support high-quality development in innovative pharmaceuticals [2] - The "Spring Rain Action," led by the National Medical Products Administration, was launched in April 2025, creating a collaborative mechanism among various departments to promote the transformation of innovative medical device results [2][3] Group 2: Innovation Ecosystem Development - Beijing has built an innovation ecosystem characterized by city-district collaboration and medical-enterprise cooperation, enhancing the internal motivation for deep collaboration between medical institutions and enterprises [4] - As of October 2025, the Beijing Medical Products Administration has collected information on 220 medical device projects, with 87 projects selected for focused cultivation, marking a new phase in the "Spring Rain Action" [4] - The collaboration mechanism ensures that innovative products are closely aligned with clinical needs from the design stage, facilitating safe and effective applications in clinical settings [6] Group 3: Product Development and Market Entry - The Beijing Medical Products Administration has implemented a "graded cultivation + review linkage" mechanism to support product market entry, providing tailored guidance for different categories of medical devices [7] - As of December 2025, one third-class medical device has entered the special review process, with four third-class devices prioritized for approval, demonstrating the effectiveness of the "Spring Rain Action" [7] - The initiative aims to create a comprehensive innovation ecosystem that integrates policy innovation, clinical resources, and industry collaboration, ensuring sustainable growth in the medical health sector [8]

企业名称嘉旭医疗科技（深圳）有限公司法定代表人詹嘉翔注册资本500万国标行业科学研究和技术服 务业>专业技术服务业>工业与专业设计及其他专业技术服务地址深圳市龙岗区龙城街道嶂背社区嶂背 路104号镱骐厂厂房第4栋1层企业类型有限责任公司(港澳台投资、非独资)营业期限2026-2-6至无固定期 限 天眼查显示，近日，嘉旭医疗科技（深圳）有限公司成立，法定代表人为詹嘉翔，注册资本500万人民 币，深圳安瑞希生物科技有限公司、深湾医创（深圳）科技有限公司持股。 经营范围含一般经营项目是：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；第一 类医疗器械生产；第二类医疗器械销售；第一类医疗器械销售；经营主体登记注册代理；软件开发；货 物进出口；技术进出口。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动），许可经营 项目是：第二类医疗器械生产；第三类医疗器械生产；医疗器械互联网信息服务。（依法须经批准的项 目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准） 序号股东名称持股比例1詹嘉翔51%2深圳安瑞希生物科技有限公司41%3深湾医创（深圳）科技有限公 司8% 来源 ...

天眼查显示，近日，南阳官庄工区南石医院有限公司成立，法定代表人为赵博，注册资本1000万人民 币，由南阳祥瑞医院管理咨询有限公司全资持股。 企业名称南阳官庄工区南石医院有限公司法定代表人赵博注册资本1000万人民币国标行业科学研究和技 术服务业>专业技术服务业>工业与专业设计及其他专业技术服务地址河南省南阳市官庄工区广南路文 体中心南150米路东房地产管理处1-01楼企业类型有限责任公司（非自然人投资或控股的法人独资）营 业期限2026-2-2至无固定期限登记机关南阳市市场监督管理局官庄工区分局 来源：市场资讯 序号股东名称持股比例1南阳祥瑞医院管理咨询有限公司100% 经营范围含许可项目：医疗服务；第三类医疗器械经营（依法须经批准的项目，经相关部门批准后方可 开展经营活动，具体经营项目以相关部门批准文件或许可证件为准）第二类医疗器械销售；第一类医疗 器械销售；康复辅具适配服务；健康咨询服务（不含诊疗服务）；卫生用品和一次性使用医疗用品销 售；个人卫生用品销售；日用百货销售；日用品销售；日用杂品销售；停车场服务（除依法须经批准的 项目外，凭营业执照依法自主开展经营活动） ...

Core Viewpoint - The company plans to establish a wholly-owned subsidiary, Xidian Pharmacy Co., Ltd., with an investment of 2 million RMB to enhance market expansion and business development [1] Group 1 - The board of directors will hold the 14th meeting of the 8th session on January 22, 2026, to review the proposal for the establishment of the subsidiary [1] - The new subsidiary will primarily engage in drug retail, the operation of Class III medical devices, and the sale of disinfectant equipment [1] - This investment aligns with the company's strategic development plan and aims to facilitate market expansion [1]

Core Viewpoint - The company is selling a 51% stake in Fujian Jianchen Pharmaceutical Co., Ltd. for RMB 1.6779 million due to declining performance and high fixed costs associated with its operations [1] Group 1: Company Actions - The company’s wholly-owned subsidiary, Zhejiang Health Road Technology Group Co., Ltd., is the entity involved in the sale [1] - The decision to sell the stake is driven by the need to reduce costs and improve efficiency amid disappointing financial performance [1] Group 2: Financial Performance - The company experienced a temporary revenue increase due to stockpiling of Oseltamivir during the flu outbreak at the end of 2023 [1] - Following the decline of the pandemic, the limitations of being a single-product pharmaceutical wholesaler became apparent, leading to a significant drop in revenue and net profit starting August 2024 [1] - Fixed costs related to drug procurement, storage, transportation, and employee salaries are relatively high, contributing to the decision to divest [1] Group 3: Future Plans - Proceeds from the sale will be used to develop the company’s enterprise services and digital marketing services [1]

Core Viewpoint - The Guangxi government has issued policies to promote the high-quality development of the biopharmaceutical industry, aiming to enhance specialization, aggregation, and intelligence in the sector, and to establish Guangxi as a significant biopharmaceutical manufacturing base for ASEAN [1] Group 1: R&D Innovation - Guangxi supports R&D innovation in the biopharmaceutical field, encouraging collaboration between enterprises and academic institutions to establish key laboratories and clinical research centers [1] - Financial support of no less than 50 million yuan is provided for newly recognized national key laboratories led by Guangxi [1] - Enterprises are incentivized to increase R&D investment, with subsidies based on the increase in R&D expenditure [1] - Support for clinical trial applicants includes up to 3 million yuan for Phase II and 5 million yuan for Phase III clinical trials for Class I innovative drugs [1] Group 2: Key Technology Development - The Guangxi technology plan includes support for the development of rare and endangered traditional Chinese medicine resources and marine biomedicine [2] - Financial support of up to 1.5 million yuan is available for generic drugs that meet specific criteria, with up to 4 million yuan for those requiring bioequivalence testing [2] Group 3: Market Development - Support is provided for establishing high-quality breeding bases and quality management standards for traditional Chinese medicine [3] - Financial incentives are available for biopharmaceutical companies achieving positive growth, with a focus on cultivating specialized and high-quality enterprises [3] - Companies are encouraged to expand into international markets, with support of up to 3 million yuan for those obtaining overseas listing qualifications [3] Group 4: Industrialization Support - Financial support is available for companies obtaining national drug or medical device registration, with varying amounts based on the classification and scale of production [4] - Support for key core technology industrialization is provided at 15% of fixed asset investment, with a cap of 20 million yuan per project [4] - The establishment of specialized pharmaceutical industrial parks is encouraged to enhance industry concentration [4] Group 5: Mechanism Improvement - The government prioritizes inspection, registration, and approval for projects included in major national and regional R&D plans [5] - Efforts are made to improve the efficiency of review and approval processes, as well as to broaden financing channels for the biopharmaceutical industry [5]